Journal
GEBURTSHILFE UND FRAUENHEILKUNDE
Volume 72, Issue 9, Pages 819-832Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0032-1315340
Keywords
biomarker; Her2/neu (human epidermal growth factor receptor); breast cancer
Categories
Funding
- Siemens Healthcare Diagnostics Products GmbH
Ask authors/readers for more resources
The therapy of choice for breast cancer patients requiring adjuvant chemo- or radiotherapy is increasingly guided by the principle of weighing the individual effectiveness of the therapy against the associated side effects. This has only been made possible by the discovery and validation of modern biomarkers. In the last decades and in the last few years some biomarkers have been integrated in clinical practice and a number have been included in modern study concepts. The importance of biomarkers lies not merely in their prognostic value indicating the future course of disease but also in their use to predict patient response to therapy. Due to the many subgroups, mathematical models and computer-assisted analysis are increasingly being used to assess the prognostic information obtained from established clinical and histopathological factors. In addition to describing some recent computer programmes this overview will focus on established molecular markers which have already been extensively validated in clinical practice and on new molecular markers identified by genomewide studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available